Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Obstet Gynecol. 2011 Feb;204(2):126.e1-4. doi: 10.1016/j.ajog.2010.09.002. Epub 2010 Oct 29.

The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study.

Author information

1
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland. oskari.heikinheimo@helsinki.fi

Abstract

OBJECTIVE:

We sought to assess the effects of long-term use and safety of the levonorgestrel-releasing (LNG)-intrauterine system (IUS) among human immunodeficiency virus (HIV)-infected women in comparison with HIV-infected women not using the device.

STUDY DESIGN:

Fifteen women using the LNG-IUS and their 25 age- and CD4(+) lymphocyte count-matched control subjects with annual follow-up data were followed up for 5 years.

RESULTS:

No unplanned pregnancies or pelvic infections occurred among the LNG-IUS users. Altogether, 12 (80%) of the LNG-IUS users continued its use up to 5 years. Annual CD4(+) lymphocyte counts were similar in the LNG-IUS users and control subjects throughout the follow-up period. The hemoglobin levels increased initially (P < .005) and remained higher among the LNG-IUS users (P < .02). Pap smears displayed non-squamous intraepithelial lesion cytology in ≥ 85% of cases in both groups.

CONCLUSION:

No unfavorable effects on the course of HIV infection were noted during long-term use of the LNG-IUS. Dual protection by means of an LNG-IUS and condoms might be an ideal contraceptive strategy for HIV-infected women.

PMID:
21035781
DOI:
10.1016/j.ajog.2010.09.002
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center